vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and Shoals Technologies Group, Inc. (SHLS). Click either name above to swap in a different company.

Shoals Technologies Group, Inc. is the larger business by last-quarter revenue ($148.3M vs $77.6M, roughly 1.9× Bioceres Crop Solutions Corp.). Shoals Technologies Group, Inc. runs the higher net margin — 5.5% vs -9.6%, a 15.1% gap on every dollar of revenue. On growth, Shoals Technologies Group, Inc. posted the faster year-over-year revenue change (38.6% vs -16.8%). Over the past eight quarters, Shoals Technologies Group, Inc.'s revenue compounded faster (27.8% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Shoals Technologies Group is a leading provider of electrical balance of systems solutions for renewable energy and e-mobility. It supplies connectivity components for solar projects, energy storage systems and EV charging infrastructure, serving clients across North America, Europe and Asia-Pacific.

BIOX vs SHLS — Head-to-Head

Bigger by revenue
SHLS
SHLS
1.9× larger
SHLS
$148.3M
$77.6M
BIOX
Growing faster (revenue YoY)
SHLS
SHLS
+55.5% gap
SHLS
38.6%
-16.8%
BIOX
Higher net margin
SHLS
SHLS
15.1% more per $
SHLS
5.5%
-9.6%
BIOX
Faster 2-yr revenue CAGR
SHLS
SHLS
Annualised
SHLS
27.8%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
SHLS
SHLS
Revenue
$77.6M
$148.3M
Net Profit
$-7.4M
$8.1M
Gross Margin
46.8%
31.6%
Operating Margin
9.3%
11.7%
Net Margin
-9.6%
5.5%
Revenue YoY
-16.8%
38.6%
Net Profit YoY
-20.2%
3.9%
EPS (diluted)
$-0.12
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
SHLS
SHLS
Q4 25
$148.3M
Q3 25
$77.6M
$135.8M
Q2 25
$110.8M
Q1 25
$60.6M
$80.4M
Q4 24
$98.8M
$107.0M
Q3 24
$93.3M
$102.2M
Q2 24
$99.2M
Q1 24
$84.0M
$90.8M
Net Profit
BIOX
BIOX
SHLS
SHLS
Q4 25
$8.1M
Q3 25
$-7.4M
$11.9M
Q2 25
$13.9M
Q1 25
$-1.6M
$-282.0K
Q4 24
$605.2K
$7.8M
Q3 24
$-6.2M
$-267.0K
Q2 24
$11.8M
Q1 24
$9.8M
$4.8M
Gross Margin
BIOX
BIOX
SHLS
SHLS
Q4 25
31.6%
Q3 25
46.8%
37.0%
Q2 25
37.2%
Q1 25
39.4%
35.0%
Q4 24
42.0%
37.6%
Q3 24
40.2%
24.8%
Q2 24
40.3%
Q1 24
50.8%
40.2%
Operating Margin
BIOX
BIOX
SHLS
SHLS
Q4 25
11.7%
Q3 25
9.3%
13.7%
Q2 25
14.4%
Q1 25
1.5%
5.4%
Q4 24
14.5%
15.4%
Q3 24
2.5%
4.4%
Q2 24
18.7%
Q1 24
15.7%
12.8%
Net Margin
BIOX
BIOX
SHLS
SHLS
Q4 25
5.5%
Q3 25
-9.6%
8.7%
Q2 25
12.5%
Q1 25
-2.6%
-0.4%
Q4 24
0.6%
7.3%
Q3 24
-6.6%
-0.3%
Q2 24
11.9%
Q1 24
11.6%
5.3%
EPS (diluted)
BIOX
BIOX
SHLS
SHLS
Q4 25
$0.05
Q3 25
$-0.12
$0.07
Q2 25
$0.08
Q1 25
$-0.02
$0.00
Q4 24
$0.00
$0.04
Q3 24
$-0.10
$0.00
Q2 24
$0.07
Q1 24
$0.14
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
SHLS
SHLS
Cash + ST InvestmentsLiquidity on hand
$15.5M
$7.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$600.0M
Total Assets
$734.9M
$904.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
SHLS
SHLS
Q4 25
$7.3M
Q3 25
$15.5M
$8.6M
Q2 25
$4.7M
Q1 25
$38.5M
$35.6M
Q4 24
$29.2M
$23.5M
Q3 24
$32.3M
$11.1M
Q2 24
$3.2M
Q1 24
$16.4M
$15.2M
Total Debt
BIOX
BIOX
SHLS
SHLS
Q4 25
Q3 25
Q2 25
Q1 25
$141.8M
Q4 24
$141.8M
Q3 24
$141.8M
Q2 24
$146.8M
Q1 24
$168.8M
Stockholders' Equity
BIOX
BIOX
SHLS
SHLS
Q4 25
$600.0M
Q3 25
$288.3M
$589.6M
Q2 25
$575.4M
Q1 25
$345.0M
$558.9M
Q4 24
$346.3M
$556.8M
Q3 24
$346.0M
$545.2M
Q2 24
$544.6M
Q1 24
$348.5M
$554.0M
Total Assets
BIOX
BIOX
SHLS
SHLS
Q4 25
$904.1M
Q3 25
$734.9M
$851.8M
Q2 25
$795.0M
Q1 25
$798.2M
$788.4M
Q4 24
$835.2M
$793.1M
Q3 24
$827.3M
$801.3M
Q2 24
$788.4M
Q1 24
$836.1M
$825.3M
Debt / Equity
BIOX
BIOX
SHLS
SHLS
Q4 25
Q3 25
Q2 25
Q1 25
0.25×
Q4 24
0.25×
Q3 24
0.26×
Q2 24
0.27×
Q1 24
0.30×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
SHLS
SHLS
Operating Cash FlowLast quarter
$14.4M
$-4.1M
Free Cash FlowOCF − Capex
$-11.3M
FCF MarginFCF / Revenue
-7.6%
Capex IntensityCapex / Revenue
4.8%
Cash ConversionOCF / Net Profit
-0.50×
TTM Free Cash FlowTrailing 4 quarters
$-16.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
SHLS
SHLS
Q4 25
$-4.1M
Q3 25
$14.4M
$19.4M
Q2 25
$-13.8M
Q1 25
$23.3M
$15.6M
Q4 24
$-5.4M
$14.0M
Q3 24
$5.2M
$15.7M
Q2 24
$37.8M
Q1 24
$-17.4M
$12.9M
Free Cash Flow
BIOX
BIOX
SHLS
SHLS
Q4 25
$-11.3M
Q3 25
$9.0M
Q2 25
$-26.0M
Q1 25
$12.3M
Q4 24
$12.5M
Q3 24
$13.3M
Q2 24
$35.8M
Q1 24
$10.4M
FCF Margin
BIOX
BIOX
SHLS
SHLS
Q4 25
-7.6%
Q3 25
6.6%
Q2 25
-23.5%
Q1 25
15.4%
Q4 24
11.6%
Q3 24
13.0%
Q2 24
36.1%
Q1 24
11.4%
Capex Intensity
BIOX
BIOX
SHLS
SHLS
Q4 25
4.8%
Q3 25
7.7%
Q2 25
11.0%
Q1 25
4.0%
Q4 24
1.4%
Q3 24
2.3%
Q2 24
2.0%
Q1 24
2.7%
Cash Conversion
BIOX
BIOX
SHLS
SHLS
Q4 25
-0.50×
Q3 25
1.63×
Q2 25
-1.00×
Q1 25
Q4 24
-8.85×
1.79×
Q3 24
Q2 24
3.21×
Q1 24
-1.78×
2.69×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

SHLS
SHLS

System Solutions$122.0M82%
Components$26.3M18%

Related Comparisons